血清多种生物标志物预测抑郁症患者在精神药物治疗中的复发。

IF 5.3 2区医学 Q1 CLINICAL NEUROLOGY

Progress in Neuro-Psychopharmacology & Biological Psychiatry Pub Date : 2025-04-02 DOI:10.1016/j.pnpbp.2025.111360

Jae-Min Kim , Hee-Ju Kang , Ju-Wan Kim , Min Jhon , Ju-Yeon Lee , Sung-Wan Kim , Min-Gon Kim , Il-Seon Shin

{"title":"血清多种生物标志物预测抑郁症患者在精神药物治疗中的复发。","authors":"Jae-Min Kim , Hee-Ju Kang , Ju-Wan Kim , Min Jhon , Ju-Yeon Lee , Sung-Wan Kim , Min-Gon Kim , Il-Seon Shin","doi":"10.1016/j.pnpbp.2025.111360","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Effective predictive biomarkers for depression relapse remain elusive. This study examined the association of a multi-modal serum biomarker panel with relapse among outpatients with depressive disorders under psychopharmacotherapy, utilizing a naturalistic 24-month prospective design.</div></div><div><h3>Methods</h3><div>atients were recruited from a University hospital in South Korea between March 2012 and April 2017. At baseline, 14 serum biomarkers along with socio-demographic and clinical characteristics were assessed in 1094 patients. Following initial antidepressant monotherapy, patients who responded (Hamilton Depression Rating Scale [HAMD] ≤ 14) at the 12-week mark (<em>N</em> = 823) were monitored for relapse (HAMD >14) every three months up to 24 months (<em>N</em> = 710). Logistic regression models, adjusted for relevant covariates, were used to evaluate predictive biomarkers of relapse.</div></div><div><h3>Results</h3><div>The combined scores of four serum biomarkers (cortisol, high-sensitivity C-reactive protein, tumor necrosis factor-alpha, and brain-derived neurotrophic factor) showed a significant and graded association with depression relapse (<em>P</em>-value <0.001), even after adjustments.</div></div><div><h3>Conclusions</h3><div>The application of a combined multi-serum biomarker panel could significantly enhance the predictability of depression relapse. Further validation of these biomarkers in diverse populations and settings is warranted to confirm their utility in clinical practice.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"138 ","pages":"Article 111360"},"PeriodicalIF":5.3000,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serum multi-biomarkers for predicting relapse in patients with depressive disorders under psychopharmacotherapy\",\"authors\":\"Jae-Min Kim , Hee-Ju Kang , Ju-Wan Kim , Min Jhon , Ju-Yeon Lee , Sung-Wan Kim , Min-Gon Kim , Il-Seon Shin\",\"doi\":\"10.1016/j.pnpbp.2025.111360\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Effective predictive biomarkers for depression relapse remain elusive. This study examined the association of a multi-modal serum biomarker panel with relapse among outpatients with depressive disorders under psychopharmacotherapy, utilizing a naturalistic 24-month prospective design.</div></div><div><h3>Methods</h3><div>atients were recruited from a University hospital in South Korea between March 2012 and April 2017. At baseline, 14 serum biomarkers along with socio-demographic and clinical characteristics were assessed in 1094 patients. Following initial antidepressant monotherapy, patients who responded (Hamilton Depression Rating Scale [HAMD] ≤ 14) at the 12-week mark (<em>N</em> = 823) were monitored for relapse (HAMD >14) every three months up to 24 months (<em>N</em> = 710). Logistic regression models, adjusted for relevant covariates, were used to evaluate predictive biomarkers of relapse.</div></div><div><h3>Results</h3><div>The combined scores of four serum biomarkers (cortisol, high-sensitivity C-reactive protein, tumor necrosis factor-alpha, and brain-derived neurotrophic factor) showed a significant and graded association with depression relapse (<em>P</em>-value <0.001), even after adjustments.</div></div><div><h3>Conclusions</h3><div>The application of a combined multi-serum biomarker panel could significantly enhance the predictability of depression relapse. Further validation of these biomarkers in diverse populations and settings is warranted to confirm their utility in clinical practice.</div></div>\",\"PeriodicalId\":54549,\"journal\":{\"name\":\"Progress in Neuro-Psychopharmacology & Biological Psychiatry\",\"volume\":\"138 \",\"pages\":\"Article 111360\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-04-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Neuro-Psychopharmacology & Biological Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0278584625001149\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0278584625001149","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：有效预测抑郁症复发的生物标志物仍然难以捉摸。本研究采用自然的24个月前瞻性设计，研究了接受精神药物治疗的抑郁症门诊患者多模式血清生物标志物面板与复发的关系。方法：2012年3月至2017年4月从韩国一家大学医院招募患者。在基线时，对1094名患者的14种血清生物标志物以及社会人口统计学和临床特征进行了评估。在最初的抗抑郁单药治疗后，在12周时（N = 823）有反应的患者（汉密尔顿抑郁评定量表[HAMD] ≤ 14）每三个月监测一次复发（HAMD bbb14），直至24 个月（N = 710）。经相关协变量调整后的逻辑回归模型用于评估复发的预测性生物标志物。结果：四种血清生物标志物（皮质醇、高敏c反应蛋白、肿瘤坏死因子- α和脑源性神经营养因子）的联合评分与抑郁症复发有显著的分级关联(p值结论：应用多血清生物标志物联合评分可显著提高抑郁症复发的可预测性。这些生物标记物在不同人群和环境中的进一步验证是有必要的，以确认它们在临床实践中的效用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Serum multi-biomarkers for predicting relapse in patients with depressive disorders under psychopharmacotherapy

Background

Effective predictive biomarkers for depression relapse remain elusive. This study examined the association of a multi-modal serum biomarker panel with relapse among outpatients with depressive disorders under psychopharmacotherapy, utilizing a naturalistic 24-month prospective design.

Methods

atients were recruited from a University hospital in South Korea between March 2012 and April 2017. At baseline, 14 serum biomarkers along with socio-demographic and clinical characteristics were assessed in 1094 patients. Following initial antidepressant monotherapy, patients who responded (Hamilton Depression Rating Scale [HAMD] ≤ 14) at the 12-week mark (N = 823) were monitored for relapse (HAMD >14) every three months up to 24 months (N = 710). Logistic regression models, adjusted for relevant covariates, were used to evaluate predictive biomarkers of relapse.

Results

The combined scores of four serum biomarkers (cortisol, high-sensitivity C-reactive protein, tumor necrosis factor-alpha, and brain-derived neurotrophic factor) showed a significant and graded association with depression relapse (P-value <0.001), even after adjustments.

Conclusions

The application of a combined multi-serum biomarker panel could significantly enhance the predictability of depression relapse. Further validation of these biomarkers in diverse populations and settings is warranted to confirm their utility in clinical practice.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Progress in Neuro-Psychopharmacology & Biological Psychiatry 医学-精神病学

CiteScore

12.00

自引率

1.80%

发文量

153

审稿时长

56 days

期刊介绍： Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject. Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated.